Catalyst Wire Dossier Catalyst Wire Dossier
CLINICAL_TRIALS research · 2026-03-12

Clinical Trial Update: A Study to Learn More About the Effects and Safety of Felzartamab Infusions in Adults With Kidney Transplants Who Have Antibody-Mediated Rejection (AMR) [Phase 3]

View source ↗

Summary

A Phase 3 study is evaluating the safety and effects of felzartamab infusions in adults with antibody-mediated rejection after kidney transplantation and is cur…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • Felzartamab (felzartamab)

Snippet

Sponsor: Biogen | Conditions: Antibody-mediated Rejection | Phase 3 | Status: RECRUITING